The global Microbiome CDMO market size is predicted to grow from US$ 1658 million in 2025 to US$ 2963 million in 2031; it is expected to grow at a CAGR of 10.2% from 2025 to 2031.
Microbiome CDMO (Contract Development and Manufacturing Organization) is an organization that specializes in providing customized manufacturing and development services to biotechnology and pharmaceutical companies. They mainly focus on providing microbiome research with the entire process from samples to commercial products, including microbiome isolation, culture, identification, storage, extraction, preparation, and related product development.
With the continuous deepening of microbiome research, more and more companies and research institutions have begun to realize the application potential of microbiome in medicine, agriculture, food, and other fields, which has brought huge market demand to the microbiome CDMO industry.
ReportPrime' newest research report, the “Microbiome CDMO Industry Forecast” looks at past sales and reviews total world Microbiome CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Microbiome CDMO sales for 2025 through 2031.
- This Insight Report provides a comprehensive analysis of the global Microbiome CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.
- This report also analyses the strategies of leading global companies with a focus on Microbiome CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Microbiome CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Microbiome CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity.
Segmentation by Type:
- Microbial CDMO
- Antibiotic CDMO
- Phage CDMO
- Bacteriocins CDMO
Segmentation by Application:
- Vaccine R&D
- Biopharmaceutical
- Cell Therapy
- Others
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration:
- Arranta Bio
- Wacker Chemie AG
- Bactera
- SGS Quay Pharma
- Biose
- EnteroBiotix
- Genome And Company
- Lallemand Health Solutions
- List Bio
- Rise BioServices
- Lonza
- MaaT Pharma
- NIZO
- Quay Pharmaceuticals
- Recipharm
Key Questions Addressed in this Report:
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market